STOCK TITAN

Recursion Pharmaceuticals, Inc. Class A - RXRX STOCK NEWS

Welcome to our dedicated news page for Recursion Pharmaceuticals Class A (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals Class A .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Recursion Pharmaceuticals Class A 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Recursion Pharmaceuticals Class A 's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
-
Rhea-AI Summary
Recursion announces acquisition of Cyclica and Valence, enhancing its capabilities in AI-enabled drug discovery. The acquisitions add industry-leading capabilities in digital chemistry, machine learning, and artificial intelligence, enabling Recursion to deploy a comprehensive drug discovery solution. The acquisitions are expected to be completed in Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
Recursion Pharmaceuticals, Inc. Class A

Nasdaq:RXRX

RXRX Rankings

RXRX Stock Data

1.98B
188.28M
5.65%
92.43%
16.95%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
SALT LAKE CITY

About RXRX

recursion pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics. our platform has resulted in the massive parallelization of drug discovery. we have deployed this platform in pursuit of drugs for the treatment of rare genetic diseases. we partner or out-license these leads to major pharmaceutical companies early in development. our horizontal business model focused on discovery accelerates our impact and reduces our costs by avoiding slow and costly in-house development, and allows us to spread risk across many new therapeutic opportunities.